Skip to main content

Advertisement

SpringerLink
Log in

Clinical features and chromosomal/genetic aberration in adult acute lymphoblastic leukemia in Japan: results of Fukuoka Blood & Marrow Transplant Group Studies ALL MRD 2002 and 2008

  • Original Article
  • Published:
International Journal of Hematology Aims and scope Submit manuscript

Abstract

Acute lymphoblastic leukemia (ALL) is a common neoplasm in children, but less frequent in adults. Since information on clinical features and genetics of adult ALL in Japan is limited, we analyzed 215 subjects aged 16–65 years with untreated ALL enrolled in the Fukuoka Blood & Marrow Transplant Group studies ALL MRD 2002 and 2008. The prevalence of ALL was bimodal, with the larger group aged 56–65 years. Immunophenotypic characterization showed B-lineage is more frequent than T-lineage ALL (78.6 vs 13.0%), with age-related differences. The proportion with BCR-ABL1 rearrangement increased progressively with age, up to 55.7% among subjects aged over 56–65 years. Rearrangements involving the KMT2A gene, ETV6-RUNX1, and TCF3-PBX1 were rare in this study cohort. The overall incidence of hyperdiploidy was only 1.7%, and there were no cases with hypodiploidy. Overall survival varied by age and cytogenetics. Older subjects and those with BCR-ABL1 tended to have inferior outcomes. In this epidemiological study of Japanese adult ALL, the majority of subjects had B-lineage ALL, the T-cell phenotype was most frequent in those aged 16–25, and BCR-ABL1 rearrangement was very common, with prevalence increasing with age. These types of adult ALL are potentially manageable with targeted therapies.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

References

  1. Howlader N, Noone A, Krapcho M, Miller D, Bishop K, Kosary C, et al. SEER cancer statistics review (CSR) 1975–2014. Bethesda, MD: National Cancer Institute; 2017.

    Google Scholar 

  2. Redaelli A, Laskin BL, Stephens JM, Botteman MF, Pashos CL. A systematic literature review of the clinical and epidemiological burden of acute lymphoblastic leukaemia (ALL). Eur J Cancer Care (Engl). 2005;14:53–62.

    Article  CAS  Google Scholar 

  3. Iacobucci I, Mullighan CG. Genetic basis of acute lymphoblastic leukemia. J Clin Oncol. 2017;35:975–83.

    Article  CAS  Google Scholar 

  4. Moorman AV, Harrison CJ, Buck GA, Richards SM, Secker-Walker LM, Martineau M, et al. Karyotype is an independent prognostic factor in adult acute lymphoblastic leukemia (ALL): analysis of cytogenetic data from patients treated on the Medical Research Council (MRC) UKALLXII/Eastern Cooperative Oncology Group (ECOG) 2993 trial. Blood. 2007;109:3189–97.

    Article  CAS  Google Scholar 

  5. Moorman AV. The clinical relevance of chromosomal and genomic abnormalities in B-cell precursor acute lymphoblastic leukaemia. Blood Rev. 2012;26:123–35.

    Article  CAS  Google Scholar 

  6. Burmeister T, Gokbuget N, Schwartz S, Fischer L, Hubert D, Sindram A, et al. Clinical features and prognostic implications of TCF3-PBX1 and ETV6-RUNX1 in adult acute lymphoblastic leukemia. Haematologica. 2010;95:241–6.

    Article  CAS  Google Scholar 

  7. Garg R, Kantarjian H, Thomas D, Faderl S, Ravandi F, Lovshe D, et al. Adults with acute lymphoblastic leukemia and translocation (1;19) abnormality have a favorable outcome with hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone alternating with methotrexate and high-dose cytarabine chemotherapy. Cancer. 2009;115:2147–54.

    Article  CAS  Google Scholar 

  8. Mancini M, Scappaticci D, Cimino G, Nanni M, Derme V, Elia L, et al. A comprehensive genetic classification of adult acute lymphoblastic leukemia (ALL): analysis of the GIMEMA 0496 protocol. Blood. 2005;105:3434–41.

    Article  CAS  Google Scholar 

  9. Mrozek K, Harper DP, Aplan PD. Cytogenetics and molecular genetics of acute lymphoblastic leukemia. Hematol Oncol Clin North Am. 2009;23(991–1010):v.

    Google Scholar 

  10. Roberts KG. Genetics and prognosis of ALL in children vs adults. Hematology Am Soc Hematol Educ Program. 2018;2018:137–45.

    Article  Google Scholar 

  11. Meyer C, Kowarz E, Hofmann J, Renneville A, Zuna J, Trka J, et al. New insights to the MLL recombinome of acute leukemias. Leukemia. 2009;23:1490–9.

    Article  CAS  Google Scholar 

  12. Nagafuji K, Miyamoto T, Eto T, Kamimura T, Taniguchi S, Okamura T, et al. Monitoring of minimal residual disease (MRD) is useful to predict prognosis of adult patients with Ph-negative ALL: results of a prospective study (ALL MRD2002 Study). J Hematol Oncol. 2013;6:14.

    Article  CAS  Google Scholar 

  13. Nagafuji K, Miyamoto T, Eto T, Ogawa R, Okumura H, Takase K, et al. Prospective evaluation of minimal residual disease monitoring to predict prognosis of adult patients with Ph-negative acute lymphoblastic leukemia. Eur J Haematol. 2019;103(3):164–71.

    Article  CAS  Google Scholar 

  14. Cataland SR, Daugherty CK, Weseman EC, Larson RA. Preliminary experience with a new chemotherapy regimen for adults with acute lymphoblastic leukemia. Leuk Lymphoma. 2009;41:297–307.

    Article  Google Scholar 

  15. Stock W, Johnson JL, Stone RM, Kolitz JE, Powell BL, Wetzler M, et al. Dose intensification of daunorubicin and cytarabine during treatment of adult acute lymphoblastic leukemia: results of Cancer and Leukemia Group B Study 19802. Cancer. 2013;119:90–8.

    Article  CAS  Google Scholar 

  16. Kanda Y. Investigation of the freely available easy-to-use software “EZR” for medical statistics. Bone Marrow Transplant. 2013;48:452–8.

    Article  CAS  Google Scholar 

  17. Moorman AV, Chilton L, Wilkinson J, Ensor HM, Bown N, Proctor SJ. A population-based cytogenetic study of adults with acute lymphoblastic leukemia. Blood. 2010;115:206–14.

    Article  CAS  Google Scholar 

  18. Siegel SE, Stock W, Johnson RH, Advani A, Muffly L, Douer D, et al. Pediatric-inspired treatment regimens for adolescents and young adults with philadelphia chromosome-negative acute lymphoblastic leukemia: a review. JAMA Oncol. 2018;4:725–34.

    Article  Google Scholar 

  19. Kebriaei P, Saliba R, Rondon G, Chiattone A, Luthra R, Anderlini P, et al. Long-term follow-up of allogeneic hematopoietic stem cell transplantation for patients with Philadelphia chromosome-positive acute lymphoblastic leukemia: impact of tyrosine kinase inhibitors on treatment outcomes. Biol Blood Marrow Transplant. 2012;18:584–92.

    Article  CAS  Google Scholar 

  20. Fielding AK, Rowe JM, Buck G, Foroni L, Gerrard G, Litzow MR, et al. UKALLXII/ECOG2993: addition of imatinib to a standard treatment regimen enhances long-term outcomes in Philadelphia positive acute lymphoblastic leukemia. Blood. 2014;123:843–50.

    Article  CAS  Google Scholar 

  21. Thomas DA, Faderl S, Cortes J, O’Brien S, Giles FJ, Kornblau SM, et al. Treatment of Philadelphia chromosome-positive acute lymphocytic leukemia with hyper-CVAD and imatinib mesylate. Blood. 2004;103:4396–407.

    Article  CAS  Google Scholar 

  22. Hatta Y, Mizuta S, Matsuo K, Ohtake S, Iwanaga M, Sugiura I, et al. Final analysis of the JALSG Ph+ALL202 study: tyrosine kinase inhibitor-combined chemotherapy for Ph+ALL. Ann Hematol. 2018;97:1535–45.

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Hematology and Oncology, Department of Medicine, Kurume University School of Medicine, 67 Asahi-machi, Kurume, 830-0011, Japan

    Satoshi Morishige & Koji Nagafuji

  2. Department of Medicine and Biosystemic Science, Kyushu University Graduate School of Medical Sciences, Fukuoka, Japan

    Toshihiro Miyamoto & Koichi Akashi

  3. Department of Hematology, Hamanomachi Hospital, Fukuoka, Japan

    Tetsuya Eto

  4. Department of Hematology, Toranomon Hospital, Tokyo, Japan

    Naoyuki Uchida

  5. Department of Hematology, HaraSanshin General Hospital, Fukuoka, Japan

    Tomohiko Kamimura

  6. Department of Hematology, Oita Prefectural Hospital, Oita, Japan

    Yasuhiko Miyazaki

  7. Department of Hematology and Oncology, Japan Community Health Care Organization Kyushu Hospital, Kitakyushu, Japan

    Ryosuke Ogawa

  8. Department of Hematology, Toyama Prefectural Central Hospital, Toyama, Japan

    Hirokazu Okumura

  9. Department of Hematology, Matsuyama Red Cross Hospital, Matsuyama, Japan

    Tomoaki Fujisak

  10. Department of Hematology and Clinical Research Institute, National Hospital Organization Kyushu Medical Center, Fukuoka, Japan

    Hiromi Iwasaki

  11. Department of Hematology, Miyazaki Prefectural Hospital, Miyazaki, Japan

    Noriaki Kawano

  12. Department of Hematology, Toranomon Hospital Kajigaya, Kawasaki, Japan

    Atsushi Wake

  13. Department of Hematology, Kitakyushu Municipal Medical Center, Kitakyushu, Japan

    Takanori Ohta

  14. Division of Medical Oncology, Hematology and Infectious Diseases, Department of Internal Medicine, Fukuoka University Hospital, Fukuoka, Japan

    Yasushi Takamatsu

  15. Department of Hematology, Toyama Red Cross Hospital, Toyama, Japan

    Toshiro Kurokawa

  16. Department of Hematology, Imamura General Hospital, Kagoshima, Japan

    Yoshikiyo Ito

  17. Center for Cellular and Molecular Medicine, Kyushu University Hospital, Fukuoka, Japan

    Takahiro Maeda

Authors
  1. Satoshi Morishige
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Toshihiro Miyamoto
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Tetsuya Eto
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Naoyuki Uchida
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Tomohiko Kamimura
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Yasuhiko Miyazaki
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Ryosuke Ogawa
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Hirokazu Okumura
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Tomoaki Fujisak
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Hiromi Iwasaki
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Noriaki Kawano
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. Atsushi Wake
    View author publications

    You can also search for this author in PubMed Google Scholar

  13. Takanori Ohta
    View author publications

    You can also search for this author in PubMed Google Scholar

  14. Yasushi Takamatsu
    View author publications

    You can also search for this author in PubMed Google Scholar

  15. Toshiro Kurokawa
    View author publications

    You can also search for this author in PubMed Google Scholar

  16. Yoshikiyo Ito
    View author publications

    You can also search for this author in PubMed Google Scholar

  17. Takahiro Maeda
    View author publications

    You can also search for this author in PubMed Google Scholar

  18. Koichi Akashi
    View author publications

    You can also search for this author in PubMed Google Scholar

  19. Koji Nagafuji
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Koji Nagafuji.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Morishige, S., Miyamoto, T., Eto, T. et al. Clinical features and chromosomal/genetic aberration in adult acute lymphoblastic leukemia in Japan: results of Fukuoka Blood & Marrow Transplant Group Studies ALL MRD 2002 and 2008. Int J Hematol 113, 815–822 (2021). https://doi.org/10.1007/s12185-021-03116-8

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12185-021-03116-8

Keywords

Search

Navigation